Lv4
580 积分 2025-03-22 加入
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
18小时前
已完结
GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy
2天前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
3天前
已完结
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
4天前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
8天前
已完结
CAR-T therapy in solid tumors
9天前
已完结
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
14天前
已完结
Chimeric antigen receptor T cell therapy for autoimmune disease
19天前
已完结
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
25天前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
25天前
已完结
皖公网安备34019202002308
